Xtx Topco LTD Tango Therapeutics, Inc. Call Options Transaction History
Xtx Topco LTD
- $2.23 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding TNGX
# of Institutions
123Shares Held
117MCall Options Held
245KPut Options Held
18.9K-
Trv Gp Iv, LLC Boston, MA16.9MShares$115 Million97.21% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA10.7MShares$73.2 Million11.21% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA10.6MShares$72.5 Million4.69% of portfolio
-
Farallon Capital Management LLC San Francisco, CA9.16MShares$62.5 Million0.21% of portfolio
-
Woodline Partners LP San Francisco, CA6.03MShares$41.1 Million0.18% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $601M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...